• Transparency Policy Issues, Medicare Part D, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy (no specific bills); H.R. 2666 MVP Act, Medicaid Drug Rebate Program.
• Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). Issues related to cell and gene therapy (no specific bills).

Duration: July 1, 2020 to January 1, 2024

General Issues: Medicare/Medicaid, Health Issues

Spending: about $860,000 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2020: U.S. Senate, House of Representatives

Related Foreign Entities: Astellas Pharma Inc. (through 100% ownership of Astellas US Holding, Inc.) (Tokyo, JPN); contribution to lobbying: $0; ownership 100%